Corcept Therapeutics Incorporated provided earnings guidance for the full year of 2022. For the period, the company expects revenue to be in the range of $400 million and $430 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.93 USD | +3.22% | +7.48% | +4.34% |
06-04 | Truist Adjusts Price Target on Corcept Therapeutics to $65 From $44, Maintains Buy Rating | MT |
05-28 | Sector Update: Health Care Stocks Retreat Tuesday Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.34% | 3.42B | |
+42.55% | 750B | |
+34.11% | 606B | |
-6.28% | 356B | |
+18.73% | 326B | |
+6.28% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.19% | 167B |
- Stock Market
- Equities
- CORT Stock
- News Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated Provides Earnings Guidance for the Full Year of 2022